Kisho

Partner Therapeutics, Inc. — Rare Disease Pipeline | Kisho | Kisho

Partner Therapeutics, Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
3-hydroxy-3-methylglutaric aciduria	Leukine	Orphan Designation	-
46,XY partial gonadal dysgenesis	Leukine	Orphan Designation	-
Finnish type amyloidosis	sargramostim	Orphan Designation	-
acute lymphoblastic leukemia	LEUKINELeukine	Orphan Designation	FDA Approved
adult embryonal tumor with multilayered rosettes, c19mc-altered	Bizengri	Orphan Designation	-
adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy	Bizengri	Orphan Designation	-
androgen insensitivity syndrome	Leukine	Orphan Designation	-
autoimmune pulmonary alveolar proteinosis	sargramostim	Orphan Designation	-
cataract 13 with adult I phenotype	Bizengri	Orphan Designation	-
hereditary pulmonary alveolar proteinosis	sargramostim	Orphan Designation	-
hypoglycemia, leucine-induced	Leukine	Orphan Designation	-
limbic encephalitis with LGI1 antibodies	Leukine	Orphan Designation	-
malignant pancreatic neoplasm	Bizengri	Orphan Designation	-
nut midline carcinoma	Bizengri	Orphan Designation	-
pediatric hepatocellular carcinoma	Leukine	Orphan Designation	-
pediatric ovarian dysgerminoma	Leukine	Orphan Designation	-
pediatric-onset Graves disease	Leukine	Orphan Designation	-
pulmonary alveolar proteinosis	sargramostim	Orphan Designation	-
stage II endometrioid carcinoma	sargramostim	Orphan Designation	-
stage IVb bladder cancer	sargramostim	Orphan Designation	-